Bristol Myers to buy RayzeBio for $4.1 billion
NEW YORK: In its second multi-billion-dollar deal struck in less than a week, Bristol Myers Squibb said this week that it will buy RayzeBio for some US$4.1 billion to boost its cancer drug business.
In addition, two months after new CEO Chris Boerner officially took charge, the company also announced, on December 22, a $14 billion buyout of schizophrenia drug developer Karuna Therapeutics.
William Blair